Genor Biopharma Holdings Limited (6998.HK)

1,370 +0,040 (+3,01%) Al cierre: 03:59PM HKT

Genor Biopharma Holdings Limited

Building 3
1690 Zhangheng Road Pudong New District
Shanghai 201203
China
86 21 6169 0700
https://www.genorbio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 104

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Feng Guo Ph.D.	CEO & Chairman	8,29M	N/A	1970
Mr. Chengyi Weng	Vice President of Finance	N/A	N/A	N/A
Mr. Qibin Liang	Chief Technology Officer	N/A	N/A	1957
Dr. Shuhua Han Ph.D.	Chief Scientist	N/A	N/A	1959
Ms. Xiaojing Zhu	Vice President of Compliance & Administration	N/A	N/A	N/A
Mr. Tong Li M.D.	Chief Medical Officer	N/A	N/A	1969
Mr. Tak Wai Ip	Company Secretary	N/A	N/A	N/A
Mr. Jun Lin	Vice President of Quality Analysis	N/A	N/A	1985
Mr. Qingtang Duan	General Manager of Yuxi Genor	N/A	N/A	1983

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en HKD.

Descripción

Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB267, and GB266 for the treatment of cancer. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.

Gobierno corporativo

El ISS Governance QualityScore de Genor Biopharma Holdings Limited, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.